Скачать с ютуб Dr. Jacques P. Tremblay | NAF Science Showcase в хорошем качестве

Dr. Jacques P. Tremblay | NAF Science Showcase

Explore a past NAF research grant awardee's funded study, gaining scientific insights about their Ataxia research. Dr. Jacques P. Tremblay presented the research, "Development of a Gene Therapy Approach for Friedreich's Ataxia by Deletion of GAA Expansion in the Frataxin Gene." on May 17, 2024. Summary: Friedreich ataxia is due to an increased number of the GAA repeats (GAAr) in a part of the frataxin gene. This reduces frataxin to 5-35% of normal levels. This induces coordination and cardiac problems, and premature death. I am proposing a direct treatment of the cause of the disease: i.e., the removal using the CRISPR/Cas9 technology of that GAAr. This will leave the frataxin gene under its natural control and this will not increase the number of frataxin genes in a given cell. Thus, there will not increase the expression of frataxin above the normal level in some cells. This is important because too high expression of frataxin is toxic for the cells. My group has recently demonstrated that the new mouse model called YG8-800 (developed by the Jackson laboratory) containing 800 GAA repeats is an excellent model of Friedreich ataxia because it has a lower expression of frataxin and more severe symptoms. My laboratory is currently trying to identify the best Cas9 protein to cut the frataxin gene before and after the GAAr to delete it from mouse and human cells in culture. We will also verify whether the CRISPR treatment is inducing unwanted cuts in other genes. We are currently trying to identify the best vector (i.e., Adeno Associated Virus (AAV), lipid nanoparticles (LNPs), extra-cellular vesicles (EVs), engineered virus like particles (eVLPs) and chitosan nanoparticles (CN)) to deliver to the YG8-800 mouse model the components of the CRISPR technology (i.e., Cas9 and sgRNA). The current experiments will permit to obtain results in a Friedreich mouse model that will lay the foundation for a completely new treatment of Friedreich ataxia. For more information on Ataxia, please visit our website: https://www.ataxia.org Become a Free NAF member! https://bit.ly/JoinNAF Follow us on Social Media! NAF Facebook:   / ataxiafounda.  . NAF Twitter:   / naf_ataxia   NAF Instagram:   / ataxiafound.  . Ataxia Subreddit:   / ataxia   About the Speaker: Jacques P. Tremblay, PhD Institution: Laval University (Université Laval, Québec) Awarded: Research Seed Money Grant, 2020 Bio: Professor Jacques P. Tremblay has obtained a PhD in Neurosciences from Univ. of California in San Diego (UCSD) in 1974. He has been working on the development of cell and gene therapies for hereditary diseases (mainly Duchenne muscular dystrophy and Friedreich's ataxia) since 1987. He has published 305 articles in peer-reviewed journals. He is very committed to the clinical application of his research work, as indicated by the conduct, in collaboration with a group of clinicians, of a Phase I clinical trial on 9 Duchenne patients. This trial demonstrated that transplantation onto normal allogeneic myoblasts led to the presence of the normal gene in muscle fibers. He received the award for best researcher in Quebec and the award for best researcher in Canada presented by Muscular Dystrophy Canada for his work on DMD. The Royal College of Physicians and Surgeons of Canada and the Canadian Society for Clinical Investigation presented me with the Henry Friesen Award. He is currently using CRISPR/Cas9 and the Prime editing technology to correct mutations in the FXN, APP, DMD, RYR1 and NKX6-2 genes. He is currently trying to identify the best delivery method (Adeno Associated Virus, extracellular vesicles, lipid nanoparticles, engineered virus like particles or chitosan nanoparticles) to deliver the components of these gene editing technologies.